Grant of Options and RSUs, and Issue of Warrants
Ondine Biomedical Inc. announced the grant of 3,121,471 Restricted Share Units to employees and executive directors, vesting upon FDA marketing approval for their nasal photodisinfection therapy. Additionally, 8,290,000 options were granted to employees, directors, and consultants with an exercise price of 13.25 pence, vesting over three years. The company also issued 1,000,000 warrants at a strike price of 15 pence, expiring six months after FDA approval. These issuances represent approximately 0.56% for RSUs, 4.73% for options, and 0.18% for warrants of the company's current issued share capital.
Select text to share a quote on X · sign in to keep highlights & notes in your OBI notes
Ondine Biomedical Inc. (LON: OBI), a Canadian life sciences company pioneering light-activated antimicrobial treatments, announces the issuance of Restricted Share Units, options and warrants below.
Grant of Restricted Share Units
On 5 June 2026, the Company granted a total of 3,121,471 Restricted Share Units ("RSUs") to employees and executive directors.
The RSUs granted to executive directors of the Company are as follows:
| Director | Position | RSUs granted | Total RSUs units now held |
|---|---|---|---|
| Carolyn Cross | C EO | 767,876 | 767,876 |
| Nicolas Loebel | C TO | 716,684 | 716,684 |
The Restricted Share Units vest upon receipt of U.S. Food and Drug Administration ("FDA") marketing approval for Ondine's nasal photodisinfection therapy for the reduction of surgical site infections.
Following the grant of the RSUs, the Company has 3,121,471 RSUs to subscribe for new common shares in the Company ("Common Shares") outstanding, which represents c.0.56% per cent of the Company's current issued share capital.
Grant of Options
On 5 June 2026, 8,290,000 Options were granted to employees, executive directors, non-executive directors and consultants.
The Options to the executive and non-executive directors are as follows:
| Director | Position | Options granted | Total Options now held |
|---|---|---|---|
| Jean Charest | Non-executive Chair | 400,000 | 740,000 |
| Jean Duvall | Non-executive Director | 250,000 | 400,000 |
| Junaid Bajwa | Non-executive Director | 250,000 | 400,000 |
| Margaret Shaw | Non-executive Director | 250,000 | 325,000 |
| Carolyn Cross | Executive Director | 2,000,000 | 4,075,000 |
| Nicolas Loebel | Executive Director | 2,000,000 | 11,575,000 |
The new Options all have an exercise price of 13.25 pence, being the closing midmarket share price on 5 June 2026 (the "Approval Date"), the day on which the grant of Options was approved by the Board. The Options vest evenly over a period of three years, with 33.33% vesting on each of the three successive anniversaries of the Approval Date and can be exercised for a period of eight years from the Approval Date.
Following the grant of the new Options, the Company has 26,528,334 Options to subscribe for new Common Shares outstanding, which represents c.4.73% per cent of the Company's current issued share capital.
Issue of Warrants
On 5 June 2026, the Company issued 1,000,000 warrants to an executive, entitling the holder to acquire Common Shares of the Company at a strike price of 15 pence each. The warrants have an expiration date of six months following receipt of U.S. Food and Drug Administration ("FDA") marketing approval for Ondine's nasal photodisinfection therapy for the reduction of surgical site infections.
Following the grant of the warrants, the Company has 1,000,000 warrants to subscribe for new Common Shares outstanding, which represents c.0.18% per cent of the Company's current issued share capital.
About Ondine Biomedical Inc.
U.S. Regulatory Status and Clinical Data Disclaimer
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.